Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Construction of Anti-hPD-L1 HCAb Nb6 and in Situ 124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma.

Huang HF, Zhu H, Li GH, Xie Q, Yang XT, Xu XX, Tian XB, Wan YK, Yang Z.

Bioconjug Chem. 2019 Oct 2. doi: 10.1021/acs.bioconjchem.9b00539. [Epub ahead of print]

PMID:
31535847
2.

Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.

Xu M, Han Y, Liu G, Xu Y, Duan D, Liu H, Du F, Luo P, Liu Z.

Mol Pharm. 2018 Oct 1;15(10):4426-4433. doi: 10.1021/acs.molpharmaceut.8b00371. Epub 2018 Sep 4.

PMID:
30133286
3.

A Novel Engineered Small Protein for Positron Emission Tomography Imaging of Human Programmed Death Ligand-1: Validation in Mouse Models and Human Cancer Tissues.

Natarajan A, Patel CB, Ramakrishnan S, Panesar PS, Long SR, Gambhir SS.

Clin Cancer Res. 2019 Mar 15;25(6):1774-1785. doi: 10.1158/1078-0432.CCR-18-1871. Epub 2018 Oct 29.

PMID:
30373750
4.

PET imaging of tumor PD-L1 expression with a highly specific non-blocking nanobody.

Lv G, Qiu L, Sun Y, Li K, Liu Q, Zhao Q, Qin S, Lin J.

J Nucl Med. 2019 Jun 28. pii: jnumed.119.226712. doi: 10.2967/jnumed.119.226712. [Epub ahead of print]

PMID:
31253743
5.

A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.

Huang A, Peng D, Guo H, Ben Y, Zuo X, Wu F, Yang X, Teng F, Li Z, Qian X, Qin FX.

Sci Rep. 2017 Feb 16;7:42687. doi: 10.1038/srep42687.

6.

PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.

Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S.

Bioconjug Chem. 2016 Sep 21;27(9):2103-10. doi: 10.1021/acs.bioconjchem.6b00348. Epub 2016 Aug 9.

7.

Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1.

Ramakrishnan S, Natarajan A, Chan CT, Panesar PS, Gambhir SS.

Protein Eng Des Sel. 2019 Oct 15. pii: gzz030. doi: 10.1093/protein/gzz030. [Epub ahead of print]

PMID:
31612217
8.

111In/68Ga-Labeled anti-epidermal growth factor receptor, native chemical ligation cyclized Affibody ZHER2:342min.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2013 Apr 3 [updated 2013 May 23].

9.

Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.

Mayer AT, Natarajan A, Gordon SR, Maute RL, McCracken MN, Ring AM, Weissman IL, Gambhir SS.

J Nucl Med. 2017 Apr;58(4):538-546. doi: 10.2967/jnumed.116.177659. Epub 2016 Dec 15.

10.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
11.

Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression.

Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, Lafont V, Tran T, Cole EL, Wright M, Kim J, Pena A, Kukral D, Dischino DD, Chow P, Gan J, Adelakun O, Wang XT, Cao K, Leung D, Bonacorsi SJ Jr, Hayes W.

J Nucl Med. 2018 Mar;59(3):529-535. doi: 10.2967/jnumed.117.199596. Epub 2017 Oct 12.

12.

Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

Natarajan A, Mayer AT, Reeves RE, Nagamine CM, Gambhir SS.

Mol Imaging Biol. 2017 Dec;19(6):903-914. doi: 10.1007/s11307-017-1060-3.

13.

Monoclonal Antibody L1Mab-13 Detected Human PD-L1 in Lung Cancers.

Yamada S, Itai S, Nakamura T, Yanaka M, Chang YW, Suzuki H, Kaneko MK, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2018 Apr;37(2):110-115. doi: 10.1089/mab.2018.0004. Epub 2018 Apr 2.

PMID:
29608408
14.

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC, Ferté C.

Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.

15.

In Vivo Imaging of the Programmed Death Ligand 1 by 18F PET.

González Trotter DE, Meng X, McQuade P, Rubins D, Klimas M, Zeng Z, Connolly BM, Miller PJ, O'Malley SS, Lin SA, Getty KL, Fayadat-Dilman L, Liang L, Wahlberg E, Widmark O, Ekblad C, Frejd FY, Hostetler ED, Evelhoch JL.

J Nucl Med. 2017 Nov;58(11):1852-1857. doi: 10.2967/jnumed.117.191718. Epub 2017 Jun 6.

16.

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody.

Li D, Cheng S, Zou S, Zhu D, Zhu T, Wang P, Zhu X.

Mol Pharm. 2018 Apr 2;15(4):1674-1681. doi: 10.1021/acs.molpharmaceut.8b00062. Epub 2018 Mar 12.

PMID:
29502426
17.

Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.

Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S.

Mol Imaging. 2019 Jan-Dec;18:1536012119852189. doi: 10.1177/1536012119852189.

18.

Dosimetry Prediction for Clinical Translation of 64Cu-Pembrolizumab ImmunoPET Targeting Human PD-1 Expression.

Natarajan A, Patel CB, Habte F, Gambhir SS.

Sci Rep. 2018 Jan 12;8(1):633. doi: 10.1038/s41598-017-19123-x.

19.

High-affinity human PD-L1 variants attenuate the suppression of T cell activation.

Liang Z, Tian Y, Cai W, Weng Z, Li Y, Zhang H, Bao Y, Li Y.

Oncotarget. 2017 Oct 10;8(51):88360-88375. doi: 10.18632/oncotarget.21729. eCollection 2017 Oct 24.

20.

Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer.

Liu B, Cao W, Qiao G, Yao S, Pan S, Wang L, Yue C, Ma L, Liu Y, Cui D.

Acta Biomater. 2019 Sep 9. pii: S1742-7061(19)30611-7. doi: 10.1016/j.actbio.2019.08.046. [Epub ahead of print]

PMID:
31513911

Supplemental Content

Support Center